Código QR (código de barras bidimensional)

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Objective To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.Materials and Methods This retrospective co...

ver descrição completa

Na minha lista:
Principais autores: Maryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven R. Feldman
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2026-12-01
coleção:Journal of Dermatological Treatment
Assuntos:
On-label persistence
psoriasis
guselkumab
advanced therapies
real-world evidence
Acesso em linha:https://www.tandfonline.com/doi/10.1080/09546634.2026.2631903
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados